Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2026)
Pliant Therapeutics (PLRX) reported Net Cash Flow of -$23.3 million for Q1 2026, down 212.08% year-over-year from $20.7 million in Q1 2025, and up 51.84% quarter-over-quarter from -$48.3 million in Q4 2025.
Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Net Cash Flow data on file, last reported at -$23.3 million in Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$23.3 million, down 212.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$69.7 million (down 211.91% YoY), and the FY2025 annual result was -$25.7 million, down 423.65% from the prior year.
- Net Cash Flow rose to -$23.3 million in Q1 2026 per PLRX's latest filing, from -$48.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $68.8 million in Q1 2023 and troughed at -$48.3 million in Q4 2025.
- A 5-year average of -$1.6 million and a median of -$5.1 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 30249.21% in 2022, then jumped 997.66% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$10.9 million in 2022, then jumped by 164.37% to $7.0 million in 2023, then tumbled by 219.75% to -$8.4 million in 2024, then sank by 472.94% to -$48.3 million in 2025, then soared by 51.84% to -$23.3 million in 2026.
- Business Quant data shows PLRX's Net Cash Flow at -$23.3 million in Q1 2026, -$48.3 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 664,983.53 |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | -23.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.26 Mn |
| Mar 31, 2026 | -23.26 Mn |
| Dec 31, 2025 | -48.29 Mn |
| Dec 31, 2025 | -48.29 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | 20.75 Mn |
| Mar 31, 2025 | 20.75 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Sep 30, 2024 | -770,000.00 |
| Sep 30, 2024 | -770,000.00 |
| Jun 30, 2024 | -33.91 Mn |
| Jun 30, 2024 | -33.91 Mn |
| Mar 31, 2024 | 51.06 Mn |
| Mar 31, 2024 | 51.06 Mn |
| Dec 31, 2023 | 7.04 Mn |
| Dec 31, 2023 | 7.04 Mn |